Spyre reported positive Phase 2 SKYLINE data for SPY003, a potential best-in-class anti-IL-23. The results met its endpoints with clinically meaningful improvements and a well-tolerated safety profile.
Spyre reported positive Phase 2 SKYLINE data for SPY003, a potential best-in-class anti-IL-23. The results met its endpoints with clinically meaningful improvements and a well-tolerated safety profile.